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doi:10.1016/j.jfma.2012.01.003Background/Purpose: The activating JAK2 mutation with a G-C to T-A transversion at codon
617 (JAK2V617F) is associated with myeloproliferative neoplasms (MPNs), including polycy-
themia vera (PV), essential thrombocythemia (ET), and myelofibrosis. Here, we report a tech-
nical advance in the diagnosis of JAK2V617F in MPNs by melting curve analysis (MCA).
Methods: From January through December 2006, we prospectively enrolled 78 patients with
PV (nZ 21), ET (nZ 32), myelofibrosis (nZ 5), secondary erythrocytosis (nZ 4), secondary
thrombocytosis (n Z 2), acute myelocytic leukemia (n Z 4), chronic myelocytic leukemia
(n Z 8), and myelodysplastic syndrome (n Z 2). Mutation analysis for JAK2V617F was per-
formed on either bone marrow or peripheral blood cells using allele-specific polymerase chain
reaction (AS-PCR) or sequencing and fluorescence resonance energy transfer (FRET) probes
with MCA.
Results: For the initial 30 samples, the detection rate of JAK2V617F using MCA was comparable
to the gold standard of the PCR sequencing methods. However, the turnaround times for MCA
and PCR were 2 hours and 2 days, respectively. The detection rate of JAK2V617F was 76.2% for
PV (homozygous in 14.3%), 46.9% for ET, 80% for myelofibrosis (homozygous in 20%), and 0% for
the other conditions. In PV, patients with homozygous JAK2V617F presented with significantly
longer disease durations than heterozygous patients. In ET, there were no differences in
the clinical parameters of patients harboring JAK2V617F compared with those with wild-type
JAK2.ematology/Oncology, Department of Medicine, Taipei Medical University-Shuang Ho Hospital, No.291,
ounty 235, Taiwan.
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Melting curve analysis of JAK2V617F 35Conclusion: Heterozygous and homozygous JAK2V617F mutations can be identified using the
rapid and reliable assay based on FRET probes and MCA. Detection of JAK2V617F can be used
to assist in the diagnosis of BCR/ABL-negative MPNs.
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Current classification methods categorize polycythemia
vera (PV), essential thrombocythemia (ET), and myelofi-
brosis as classic BCR-ABL-negative myeloproliferative
neoplasms (MPNs).1 Unlike BCR-ABL-positive chronic
myeloid leukemia (CML), these three MPNs are not associ-
ated with a specific cytogenetic abnormalities. Recent
studies on humans have identified an amino acid substitu-
tion (V617F) in the JH2 pseudokinase domain of JAK2 in
most patients with PV and in a significant number of
patients with ET and myelofibrosis.2e7 Functionally, the
V617F mutation enhances JAK2 kinase activity and confers
erythropoietin hypersensitivity to affected cells. In vivo,
mice transplanted with bone marrow cells expressing the
JAK2V617F mutation develop PV. These data suggest that the
JAK2V617F mutation could play a major role in the patho-
genesis of MPNs. However, its occurrence is uncommon in
other myeloid disorders such as CML, chronic myelomono-
cytic leukemia (CMML), myelodysplastic syndrome (MDS),
and acute myelocytic leukemia (AML).8e10
In the working diagnosis of thrombocytosis or eryth-
rocytosis, secondary causes should first be excluded.1
Thrombosis and vasomotor symptoms are most frequently
seen in ET and PV, rather than secondary conditions. In
asymptomatic patients, the initial differential diagnosis of
primary or secondary thrombocytosis or erythrocytosis is
sometimes difficult. JAK2V617F has became the consensus
criterion for the diagnosis of MPNs, but the impact of the
JAK2 mutation on clinical presentation and prognosis is still
debated.3,4,11
The early diagnostic technique for JAK2V617F was a two-
step procedure: allele-specific PCR followed by sequencing
to determine the heterozygous or homozygous mutant
type. Recently, some investigators have applied real-
time PCR on the LightCycler (Roche Diagnostics, GmbH,
Mannheim, Germany) platform to rapidly and reliably
detect JAK2V617F using melting curve analysis (MCA).12e14
In this study, we confirmed that JAK2V617F can be quickly
detected using fluorescence resonance energy transfer
(FRET) probes. We also examined the clinical relevance of
JAK2V617F in the patient cohort of this study.
Materials and methods
Patients
Peripheral blood or bone marrow samples were drawn from
patients who were clinically suspected of having MPNs.
A cohort of 78 patients, which included 21 cases of PV,
32 cases of ET, five cases of myelofibrosis, four cases
of secondary erythrocytosis, two cases of secondarythrombocytosis, four cases of AML, eight cases of CML, and
two cases of MDS, was enrolled to investigate the incidence
of the JAK2V617F mutation. The wild-type control cell was
acute myelocytic leukemia cell line HL-60. The homozygous
mutant (JAK2V617F/JAK2V617F) control cell was eryth-
roleukemia cell line HEL. The HL-60 and HEL cell lines were
obtained from the Food Industry Research and Develop-
ment Institute, Hsinchu City, Taiwan. Four healthy adults
without hematological disorders served as non-MPN patient
controls. All patients gave written informed consent before
their inclusion in this study. DNA was isolated from whole
blood samples using the QIAamp DNA Blood Midi Kit
(Qiagen, Valencia, CA, USA). The medical records of the
subjects were reviewed and routine hematology, serum
biochemistry, and clinical presentations were evaluated at
the time of study. The study was performed in accordance
with the Helsinki agreement and was approved by the
institutional review board of Tri-Service General Hospital,
Taipei, Taiwan.
DNA extraction
DNA was extracted from leukocytes using the QIAamp DNA
Blood Mini Kit (Qiagen). Approximately 20 mL of whole
blood was used to prepare buffy coat cells by centrifugation
at 2500 g for 10 minutes at room temperature. The leuko-
cyte layer was collected, the cells were lysed, and DNA was
extracted according to the kit’s protocol. DNA samples
were stored at -20C in DNAse-free, RNAse-free distilled
water until analysis could be performed.
Genotyping by allele-specific PCR (AS-PCR)
AS-PCR was performed using two forward primers and one
common reverse primer that was described in a previous
study.5 The sequences of the primers and probes are listed
in Table 1. The first forward primer for AS-PCR, which
contains a mismatch on the third nucleotide at the 30-end,
is specific to the mutant allele and produces an amplicon of
203 base pairs (bp). The second primer generates a 364-bp
product from both the mutant and wild-type alleles and,
thus, serves as an internal PCR control. Eighty nanograms of
patient DNA was amplified using 0.4 mmol/L of a common
reverse primer and 0.2 mmol/L of two forward primers in
a PCR buffer containing 1.0 mmol/L deoxynucleoside
triphosphates (dNTPs), 2.5 mM MgCl2, and 0.2 units Taq DNA
polymerase (Applied Biosystems, Foster City, CA, USA) in
a reaction volume of 50 mL. The PCR conditions were as
follows: denaturation at 94C for 5 minutes, then 35 cycles
at 95C for 1 minute, 5C for 30 seconds, 72C for 40
seconds, and the final elongation at 72C for 5 minutes.
Amplicons were separated by size using gel electrophoresis
in order to determine the presence of mutant alleles.
Table 1 The JAK2V617F sequences of primers and probes using in LightCycler and AS-PCR.
AS-PCR
Forward (specific) 50-AGCATTTGGTTTTAAATTATGGAGTATATT-30
Forward (internal control) 50-ATCTATAGTCATGCTGAAGTAGGAGAAA-30
Reverse 50-CTGAATAGTCCTACAGTGTTTTCAGTTTCA-30
LightCycler
Forward primer 50-GGCAGAGAGAATTTTCTGAAC-30
Reverse primer 50-GCTTTCCTTTTTCACAAGATA-30
Sensor probe 50-GTCTCCACAGAAACATACTCCATAA-30
Anchor probe 50-AAAACCAAATGCTTGTGAGAAAGCT-30
AS-PCR, allele-specific polymerase chain reaction.
36 C.-L. Ho et al.Genotyping by MCA using LightCycler
The design of the primers and probes for the melting curve
assay uses the GenBank sequence AL161450 and was opti-
mized using LightCycler software (TIB MOLBIOL, Berlin,
Germany). One probe was labeled at the 50-end with
a LightCycler Red fluorophore (LightCycler Red 640); this
probe was also 30-phosphorylated. The other probe was
labeled at the 30-end with fluorescein (donor fluorophore).
The sequences of the primers and probes are listed in
Table 1. PCR was performed in capillary tubes in a total
reaction volume of 20 mL containing 80 ng of genomic DNA,
0.5 mM of the forward primer, 0.3 mM of the reverse primer,Figure 1 Validation and optimization of allele-specific polymera
sequencing of three cases. Case 1: wild-type JAK2 is represented by
presence of a G nucleotide by sequencing (arrow). Case 2: heteroz
203 bp by AS-PCR, two peaks over 58.8C and 62.3C by MCA, and
zygous JAK2 mutant is represented by two bands of 364 bp and
substitution of T for G by sequencing (arrow).0.2 mM of the sensor and anchor probes, respectively, and
1 LightCycler-FastStart DNA Masterplus HybProbe Master-
Mix (Roche Diagnostics GmbH, Mannheim, Germany). PCR
was performed under the following conditions: initial
denaturation at 95C for 10 minutes, then 40 amplification
cycles at 50C for 10 seconds with elongation at 72C for 10
seconds. MCA was performed at a denaturing temperature
of 95C for 10 seconds and a cooling temperature of 40C
for 30 seconds, followed by heating at a rate of 0.1C/
second from 55C to 70C. Using the titration method,3
a heterozygous mutation was defined by the presence of
two temperature peaks and a homozygous mutation was
defined by the presence of one temperature peak.se chain reaction (AS-PCR), melting curve analysis (MCA), and
one 364-bp band by AS-PCR, a peak at 58.8C by MCA, and the
ygous JAK2 mutant is represented by two bands at 364 bp and
mixed G/T nucleotides by sequencing (arrow). Case 3: homo-
203 bp by AS-PCR, one peak over 62.3C by MCA, and the
Figure 2 Results of the dilution of a homozygous-positive HEL cell line diluted in wild-type DNA. The sensor probes were designed
to match the mutant sequence in the target DNA. The homozygous type is represented by the higher temperature (Tm) of 62.3C,
the wild type is represented by the lower Tm of 58.8c, and the heterozygous type is the median. The 10% concentration (black
line) was defined as a weakly positive heterozygous JAKV617F mutant.
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The PCR products of the total reaction volumes were run
on 2% agarose gels containing ethidium bromide, and
the bands were excised and purified using the Geneaid
gel extraction kit (Qiagen, Hilden, Germany). In general, the
PCR products were sequenced on both strands using the
BigDye Terminator V3.1 Cycle Sequencing Kit (Applied Bio-
systems) and the same primers used as those used for PCR.
The reaction mixture included 100 ng of the PCR template,
50 ng primer, 1 mL BigDye mix, and 1 mL 5 reaction buffer in
a 10-mL volume. The PCR reactions were performed in
a GeneAmp PCR System 2700 thermal cycler (Applied Bio-
systems) using the following parameters: initial denaturation
at 96C for 1 minute, 45 cycles with 96C denaturation for 10
seconds, 50C annealing for 10 seconds, and 60C elongation
for 4 minutes. The sequenced products were analyzed using
an ABI 3730xl DNA analyzer (Applied Biosystems).
Statistical analysis
Fisher exact and Chi-square tests were used to compare
differences in the nominal variables. Both the Mann-
Whitney U-test and the Kruskal-Wallis test were used to
assess whether the continuous variables were significantly
different between categories. Differences were consideredTable 2 JAK2V617F mutation prevalence in myeloproliferative d
Diagnosis N Homozygous mutant (%) Heterozygo
PV 21 3 (14.3%) 13 (61.9%)
ET 32 0 15 (46.9%)
Myelofibrosis 5 1 (20%) 3 (75%)
AML 4 0 0
CML 8 0 0
MDS 2 0 0
PV, polycythemia vera; ET, essential thrombocythemia; AML, acute
dysplastic syndrome.significant at p < 0.05. All data were analyzed using Stat-
view software version 5.01 (SAS, Cary, NC, USA).
Results
Assay validation, optimization, and performance of
MCA and PCR sequencing
To validate the MCA assay, DNA samples from the initial
30 patients, representing three different genotypes, were
genotyped before being subjected to the MCA assay.
Comparisons of the obtained results with these two
methods showed 100% concordance (Fig. 1). The remaining
patient samples were subjected to the MCA assay prior to
the “gold standard” PCR sequencing methods for compar-
ison. The mutant allele was detected in the MCA assay using
a sensor probe designed to match the mutant sequence (T)
in the target DNA (Fig. 2). To optimize the MCA assay, we
used asymmetric PCR with a high concentration (0.5 mM) of
the forward primer and a low concentration (0.3 mM) of
the reverse primer. This strategy favors the synthesis of the
strand that binds the HybProbe pair and improves the
subsequent MCA.12e14 The mean Tm of the JAK2 wild-type
amplicon was 58.8  0.07C and the mean Tm of the
JAK2V617F mutant amplicon was 62.3  0.03C (data not
shown).isorders by melting curve analysis.
us mutant (%) Wild type (%) Prevalence of JAK2V617F
5 (23.8%) 76.2%
17 (53.1%) 46.9%
1 (20%) 80%
0 0
0 0
0 0
myeloid leukemia; CML, chronic myeloid leukemia; MDS, myelo-
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38 C.-L. Ho et al.The detection rate of JAK2V617F using MCA was compa-
rable to that using the PCR sequencing method (Fig. 1).
However, the turnaround time for MCA was approximately
2 hours compared with 2 days for PCR sequencing.
To verify the precision of the JAK2 LightCycler assay,
real-time PCR amplification and DNA MCA were repeated
three times in independent experiments using the control
HEL cell line and AML patient DNA.
Sensitivity of the detection of the JAK2V617F
mutant genotype
The sensitivity of the JAK2 LightCycler assay for identifying
low concentrations of the V617F allele was evaluated by
mixing decreasing amounts of homozygous mutant DNA
from HEL cells with increasing amounts of wild-type DNA
from HL-60 cells at ratios of 100:0, 90:10, 75:25, 50:50,
25:75, 10:90, and 0:100. The DNA mixtures with decreased
proportions of mutant alleles were then amplified by
real-time PCR and analyzed by MCA in triplicate in three
independent experiments. Using the titration method,
a separate and distinct peak at Tm 58.8C was reproducibly
detected at a wild-type allele concentration of 10%. Simi-
larly, a separate and distinct Tm peak was detected at
62.3C, even as the mutant allele concentration fell to 10%
(Fig. 2). Therefore, the presence of two Tm peaks at
58.8C and 62.3C was defined as the heterozygous geno-
type, whereas the detection of a single peak at either Tm
was defined as the homozygous genotype. This level of
sensitivity for the detection of the mutant allele may differ
between laboratories.12e14
Prevalence of JAK2V617F in MPNs and clinical
correlations
The prevalence of JAK2V617F in MPNs and other hemato-
logical malignancies is shown in Table 2. In PV patients, the
prevalence was 76.2%, which included the homozygous
mutant (14.3%) and heterozygous mutant genotypes
(61.9%). The clinical correlates between homozygous and
heterozygous PV patients and controls showed a signifi-
cantly longer disease duration in patients with homozygous
JAK2V617F than other groups of patients (Table 3). There
were no other significant correlations with the other clin-
ical laboratory variables that were examined.
In ET patients, the prevalence of JAK2V617F was 46.9%,
all of whom were heterozygous. There were no significant
associations between presence of the JAK2V617F mutation
and the clinical features of ET, age, sex, or thrombosis
history (Table 4).
In the small sample of patients with myelofibrosis, the
prevalence of JAK2V617F was 80%, with one case being
homozygous. No instance of JAK2V617F was detected in any
patients with AML, CML, MDS, secondary erythrocytosis, or
thrombocytosis.
Discussion
The current standard method for analyzing the JAK2
mutation is allele-specific PCR with genotype sequencing.
Table 4 JAK2V617F mutation and clinical characteristics in essential thrombocythemia.
Variable Heterozygous mutant Wild type p
Age (y) (median, range) 71 (22e84) 57 (32e89) 0.58
Sex (F/M) 8/8 11/5 0.28
Hgb g/dL (median, range) 13.4 (11.2e16.1) 13 (10.2e15.8) 0.22
Leukocyte (109/L) (median, range) 7590 (4490e14,900) 7140 (2820e11,900) 0.26
Platelet (109/L) (median, range) 714,000 (189,000e1,518,000) 539,000 (265,000e1,194,000) 0.65
Disease duration (mo) 12 (1e120) 12 (1e72) 0.95
Thrombosis history (no.) 5 3 0.24
Splenomegaly (no.) 4 1 0.15
Melting curve analysis of JAK2V617F 39Although the results are usually 100% accurate, such
a method requires an extended period of time. With MCA,
there is no need for further postprocessing. Thus, less time
is spent identifying the point mutation. In the current
study, the turnaround time was approximately 2 hours. This
could assist in the validation of the clinical diagnosis of
MPN. The presence of JAK2V617F may have diagnostic value
for MPNs, particularly when the clinical or morphological
findings are equivocal. A negative test result does not
completely exclude the possibility of an MPN, so if clinical
suspicion of MPN remains high, these patients should be
analyzed using this assay in order to determine if the
number of cells bearing the mutant allele increases over
time.
The advantages of MCA for the detection of JAK2
mutations have been previously reported.12e14 Although
our study did not utilize a novel design, we observed
a specific melting curve using the mutant type-specific
sensor probe. We prefer to use a probe for mutants,
especially for disease-related mutation assays, because an
increase in the melting temperature is much more signifi-
cant than a decrease in temperature.
In addition to the diagnostic value of this JAK2mutation,
its clinical correlation with MPNs has been previously
studied, although there were no common clinical findings
in different studies.3e7 It was previously reported that
the presence of homozygous JAK2V617F is associated with
longer disease duration,3 but otherwise the clinical mani-
festations are not significantly different between patients
with heterozygous and homozygous mutations. Our study
provides limited information regarding the clinical rele-
vance of JAK2V617F because of the small number of patients
analyzed. Regarding PV, homozygous JAK2V617F patients had
significantly longer disease durations than heterozygous
patients. In ET, there were no clear associations between
JAK2V617F and any clinical parameters. In this study, five
patients were diagnosed with wild-type PV, even if the
disease duration was short (1e8 months) because three had
thrombosis and two had splenomegaly.
The definitions of heterozygous and homozygous muta-
tions made by Vannuchi et al were based on a semi-
quantitative assay used to detect the amount of the mutant
allele.15 Instead, we used a qualitative assay and MCA
analysis based on our available capabilities. We defined
a heterozygous mutation as the presence of two peaks and
a homozygous mutation as the presence of one peak. These
different detection methods could contribute to different
results in the respective clinical analyses. In the future,allele-burdened quantitative assays of JAK2 mutants could
be available for use in clinical studies.
Although the molecular pathogenesis of MPNs has yet
to be identified, JAK2V617F may, in the future, become
a stepping stone for designing MPN treatments. The novel
use of FRET and MCA significantly reduced the time
required to analyze data. Even though its use may not yet
be fully recognized in the clinic, progress in biotechnology
may lead to new ideas regarding the mechanisms of these
diseases. From a therapeutic standpoint, the demonstra-
tion of JAK2V617F might dictate a clinical trial on small
molecular tyrosine kinase inhibitors as they become
available.
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